問卷

TPIDB > Principal Investigator

Principal Investigator


Kuang Tien General Hospital (在職)

Division of Nephrology

Division of Endocrinology

Division of Neurology

更新時間:2023-09-19

曾士婷
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

20Cases

2025-12-01 - 2027-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2015-05-01 - 2021-05-01

Phase IV

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2023-06-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
19Sites

Recruiting19Sites

2024-01-16 - 2026-06-30

Phase III

Active
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes
  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    CagriSemaTirzepatide

Participate Sites
7Sites

Recruiting7Sites

2020-10-01 - 2024-12-31

Phase III

Completed
Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease
  • Condition/Disease

    Diabetes Mellitus, Type 2/Peripheral Arterial Disease

  • Test Drug

    Semaglutide 1.34 mg/ml / placebo

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting1Sites

Terminated4Sites

2024-02-01 - 2028-12-31

Phase III

Active
A Phase III, Randomised, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure
  • Condition/Disease

    Chronic Kidney Disease and Hypertension

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
11Sites

Not yet recruiting5Sites

Recruiting6Sites

2008-07-01 - 2010-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

1 2